About Us
Submissions
Advertising
SIGN IN
|
SUBSCRIBE
ISSUE
CURRENT
ARCHIVE
SUPPLEMENTS
JADPRO LIVE
2020
JADPRO Live 2019 Activities
JADPRO Live 2018 Activities
CE
RESOURCES
Myelofibrosis: Narratives on Collaboration
NSCLC
HDMTX-Induced AKI
Relapsed/Refractory Multiple Myeloma
Management of irAEs
Managing Classical Hodgkin Lymphoma
Updates in Heme Malignancy Side Effects
Myeloproliferative Neoplasms Updates
Knowledge Center: Oral Oncolytics
APSHO EMPOWERED
CAREER CENTER
Narratives: HER2-Positive Breast Cancer
QUICK TIPS
HIGHLIGHTS
PODCAST
Learn more on this topic:
Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer
At what point does a patient become a candidate for treatment with CDK inhibitors?
Lee S. Schwartzberg, MD, FACP
West Cancer Center
Related Material
What are the most common side effects of CDK inhibitors?
What do APs need to know about hematologic side effects and how to manage them?
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.
